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APOBEC3G (A3G) and related cytidine deaminases are potent inhibitors of retroviruses. HIV-1 Vif hijacks the cellular Cul5-E3 ubiquitin
ligase to degrade APOBEC3 proteins and render them ineffective against these viruses. Here, we report that HIV-1 Vif is a novel zinc-binding
protein containing an H-x5-C-x17–18-C-x3–5-H motif that is distinct from other recognized classes of zinc fingers. Zinc-binding stabilized a
conserved hydrophobic interface within the HCCH motif that is critical for Vif-Cul5 E3 assembly and Vif function. An N-terminal region in the
first Cullin repeat of Cul5, which is dispensable for adaptor ElonginC binding, was required for interaction with Vif. This region is the most
divergent sequence between Cul2 and Cul5, a factor that may contribute to the selection of Cul5 and not Cul2 by Vif. This is the first example of a
zinc-binding substrate receptor responsible for the assembly of a Cullin-RING ligase, representing a new target for antiviral development.
© 2006 Elsevier Inc. All rights reserved.Keywords: Vif; Cullin; APOBEC3G; Zinc fingerIntroduction
APOBEC3G (A3G) belongs to a family of proteins with
cytidine deaminase activity that includes APOBEC1, APO-
BEC2, AID, and other APOBEC3 proteins (Bieniasz, 2004;
Goff, 2003; Harris and Liddament, 2004; Jarmuz et al., 2002;
Navarro and Landau, 2004; Rose et al., 2004; Turelli and Trono,
2005). A3G is a dominant cellular antiviral factor present in the
natural target cells of HIV-1 (Sheehy et al., 2002). In the absence
of Vif, A3G is incorporated into budding virions, where, upon
infection of new target cells, it induces cytidine deamination in
the minus-strand viral DNA (Harris et al., 2002, 2003; Lecossier
et al., 2003; Mangeat et al., 2003; Yu et al., 2004b; Zhang et al.,
2003) and may mediate other undefined antiviral functions,
resulting in abortive infection (Newman et al., 2005).⁎ Corresponding author. Department of Microbiology and Immunology, Johns
Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore,
MD 21205, USA. Fax: +1 410 614 8263.
E-mail address: xfyu@jhsph.edu (X.-F. Yu).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.02.002APOBEC3 proteins are potent inhibitors of a wide range of
retroviruses and retroelements (Bishop et al., 2004; Doehle et al.,
2005; Esnault et al., 2005; Harris et al., 2003; Kobayashi et al.,
2004; Kremer et al., 2005; Langlois et al., 2005; Lecossier et al.,
2003; Liddament et al., 2004; Mangeat et al., 2003; Mariani et
al., 2003; Noguchi et al., 2005; Rosler et al., 2004, 2005;
Schumacher et al., 2005; Suspene et al., 2004, 2005; Turelli et
al., 2004a, 2004b; Wiegand et al., 2004; Yu et al., 2004a, 2004b;
Zhang et al., 2003; Zheng et al., 2004). HIV-1 Vif recruits the
Cullin5-ElonginB-ElonginC E3 ubiquitin ligase to target the
cellular antiviral proteins A3G and APOBEC3F (A3F) for
degradation (Conticello et al., 2003; Kobayashi et al., 2005; Liu
et al., 2005; Marin et al., 2003; Mehle et al., 2004a, 2004b;
Sheehy et al., 2003; Stopak et al., 2003; Yu et al., 2003, 2004c).
Cullin-based E3 ubiquitin ligases are modular enzymes that
act as a scaffolding to bring a specific substrate into close
proximity to the E2 ubiquitin-conjugating enzyme, thereby
facilitating ubiquitination and subsequent proteasomal degra-
dation (Skowyra et al., 1997). There are seven known human
Cullin proteins, Cul1, 2, 3, 4a, 4b, 5, and 7, with diverse
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and regulation of developmental processes (Petroski and
Deshaies, 2005). Substrate specificity is determined by the
combinatorial nature of E3 ligase assembly. In the case of Cul1,
diversity is achieved by the assembly of different F-box proteins
with Cul1 through a single Skp1 adaptor protein (Zheng et al.,
2002). Cul3 is unique among Cullin proteins in having one
protein with two domains, one domain functioning as an
adaptor, forming an interface with Cul3, and the other acting as
a substrate receptor (Furukawa et al., 2003; Geyer et al., 2003;
Pintard et al., 2003, 2004; Xu et al., 2003). Cul2 and Cul5 are
interesting in that they both utilize ElonginB/C adaptor proteins;
with the BC box motif of the substrate receptor forming an
interface with a hydrophobic binding pocket in ElonginC. This
raises the question: what determines the selection of a particular
Cullin (Kamura et al., 1998)?
HIV/SIV Vif has been shown to specifically assemble with
Cul5, while the Von Hippel Lindau tumor suppressor (VHL)
has been shown to select Cul2, suggesting that an additional
interface between Cullin and the substrate receptor is
responsible for Cullin specificity (Kamura et al., 2004; Yu et
al., 2004c). In a series of elegant experiments, Kamura et al.
(2004) demonstrated the involvement of a motif downstream
from the BC-box, which they termed the Cul2- and Cul5-
boxes, in Cullin selection. Inspection of primate lentiviral Vif
proteins did not reveal a convincing Cul5-box. Instead, we
identified a completely conserved H-x5-C-x-17–18-C-x3–5-H
motif spanning 30 amino acids in HIV/SIV Vif (Luo et al.,
2005). This HCCH motif is located just upstream of the BC-
box (SLQ motif) in Vif. Amino acid substitution of each His
or Cys resulted in the loss of Vif function. Mutant Vif could no
longer suppress the antiviral activity of A3G despite retaining
the ability to interact with A3G. The ability of Vif mutants to
interact with the ElonginB/C complex was unaltered. Howev-
er, all of the Vif mutants lost the ability to interact with Cul5
(Luo et al., 2005).
The HCCH motif in Vif has the potential to bind zinc.
However, the arrangement of the His and Cys residues and the
spacing between them are different in this motif from those in
all previously identified zinc-binding domains (Krishna et al.,
2003). In the present study, we have demonstrated that HIV-1
Vif is indeed a zinc-binding protein and that the HCCH motif is
a zinc-binding domain that is required for Cul5 selection, A3G
degradation, and viral infectivity. The structures of very small
protein domains are frequently stabilized by the formation of
zinc-binding domains (Krishna et al., 2003). We hypothesized
that protein domains within the HCCH motif may be stabilized
by zinc binding, thereby fostering the Cul5 interaction.
Consistent with this idea, a hydrophobic interface within the
HCCH motif was identified as essential for selective interaction
between Vif and Cul5. Furthermore, we have demonstrated that
a region of Cul5 downstream from the ElonginC interface is
required for Vif interaction. Our data provide new insights into
the mechanism of assembly of virus-specific Cullin-RING E3
ligases. Unique motifs in Vif, which are absent from cellular
proteins, could potentially serve as targets for the development
of novel therapeutics.Results
HIV-1 Vif is a novel zinc-binding protein
A highly conserved H-x5-C-x17–18C-x3–5-H motif in primate
lentiviral Vif proteins (Fig. 1A) is required for assembly of the
Vif-Cul5 E3 ubiquitin ligase, which suppresses autologous A3G
(Luo et al., 2005). This HCCH motif is reminiscent of a zinc-
binding like structure (Fig. 1B). However, the arrangement of
the His and Cys residues and the spacing between them in Vif
appear to be novel when compared to those of other known
classes of zinc-binding domains (Fig. 1C). To determine
whether HIV-1 Vif is a true zinc-binding protein, we expressed
and purified wild-type and HCCH mutant Vif proteins and
analyzed them in a 65Zn blotting assay. 15 μg of purified Vif and
its mutants were treated with factor Xa to remove the MBP tag,
separated by SDS PAGE, and transferred to nitrocellulose. The
proteins were then blotted with 65Zn (Fig. 2A, lanes 3–4). 10 μg
each of carbonic anhydrase and soybean trypsin inhibitor was
used as positive (Fig. 2A, lane 1) and negative controls (Fig.
2A, lane 2), respectively. Wild-type Vif bound zinc efficiently
(Fig. 2A, top panel, lane 3). In repeated experiments, zinc
binding to Vif-HCCH/LSSL (Fig. 2A, lane 4) was reduced to
undetectable levels when compared to the wild-type Vif. As
expected, carbonic anhydrase bound zinc while soybean trypsin
inhibitor did not (Fig. 2A, top panel, lanes 1 and 2).
To further confirm that HIV-1 Vif has the ability to bind zinc,
we subjected purified recombinant wild-type and HCCHmutant
Vif proteins to zinc affinity chromatography. A control column
was constructed with resin that had not been charged with zinc.
Wild-type Vif bound to the column containing zinc (Fig. 2B,
lane 3) while the zinc binding of mutant Vif, Vif-HCCH/LSSL
(Fig. 2B, lane 4) was reduced to undetectable levels; neither
protein bound to the control column (Fig. 2B, lanes 5–6).
Together, these data indicate that HIV-1 Vif is a zinc-binding
protein and that the conserved HCCH motif in HIV-1 Vif
represents a novel zinc-binding domain.
A highly conserved hydrophobic motif within the HIV-1 Vif
zinc-binding domain is required for Vif-Cul5 E3 ligase
formation and Vif function
The structures of very small protein domains are frequently
stabilized by the formation of zinc fingers (Krishna et al., 2003).
We hypothesized that protein domains within the HCCH motif
may be stabilized by zinc binding, thereby mediating the
interaction with Cul5. Examination of primate lentiviral Vif
proteins revealed a highly conserved stretch of hydrophobic
residues with consensus F-X4-Φ-X2-A-Φ between the two
cysteines of the zinc-binding domain (Fig. 3A). Phe115 is
present in most lentiviral Vif proteins, with Trp occasionally
seen. Either an Ile or Val is present at position 120. Positions
123 and 124 are Ala/Leu, Ala/Ile, or Ala/Val (Fig. 3A). This
region of the zinc-binding domain is predicted to be helical by
secondary structure prediction consensus programs. Taking into
account the possible helical structure of this region, one could
predict that these well-spaced hydrophobic residues would be
Fig. 1. The conserved HCCH motif in HIV Vif represents a novel zinc finger. (A) HIV/SIV Vif contains a conserved HCCH motif, upstream of the BC-box, spanning
30 amino acids. The central region of the HCCH motif is predicted to form a helix with a hydrophobic face. (B) Hypothesized structure of HIV-1 Vif zinc-binding
domain. Residues in bold indicate point mutations. (C) HIV Vif contains a novel zinc-binding domain. The HCCHmotif was compared to all known zinc finger motifs
in terms of His/Cys order and spacing. The zinc fingers listed are categorized by structural similarity. A * indicates that the zinc finger is formed by a tertiary structure
composed of two distant regions of the protein at that point. Zinc finger classification and alignments used for consensus generation were modified from Krishna et al.
(2003).
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protein interaction.
In order to evaluate the function of this highly conserved
hydrophobic motif, we constructed four HIV-1 Vif mutants:
F115A, I120S, AL123/124SS, and RK121/122AA (Fig. 3A).
The RK121/122AA mutant was constructed to evaluate the
role of non-hydrophobic residues possibly on the opposite
face of the proposed helix. 293T cells were transfected with
wild-type or mutant Vif expression vectors. The Vif proteins
were then immunoprecipitated, and co-precipitation of Cul5,
ElonginB, and ElonginC was examined by immunoblotting.
While wild-type and hydrophobic mutant Vif proteins co-
precipitated ElonginB and ElonginC (Fig. 3B, lanes 1–4),only wild-type Vif retained the ability to interact with Cul5
(Fig. 3B, lane 1). This finding suggests that the hydrophobic
motif forms an interface that is required for Cul5 selection but
not ElonginB/C interaction. In order to evaluate whether this
interface was functional, we evaluated the ability of wild-type
and mutant Vif proteins to degrade A3G. While wild-type Vif
was able to efficiently degrade its substrate, A3G (Fig. 3C,
lane 1), all hydrophobic mutants were defective in degrading
A3G (Fig. 3C, lanes 2 to 4) when compared to the control
(Fig. 3C, lane 5). All mutant Vif proteins that were defective
in A3G degradation retained the ability to interact with A3G
(Fig. 3D, lanes 2 to 4). The hydrophobic mutants were unable
to suppress the antiviral activity of A3G, whereas disruption
Fig. 2. HIV Vif binds zinc through its HCCH motif. (A) The HCCH motif is
required for zinc coordination. 15 μg of recombinant Vif proteins, WT-Vif, and
Vif-HCCH/LSSL, were treated with factor Xa to remove the MBP tag followed
by fractionation by SDS-PAGE and transfer to nitrocellulose. Immobilized
proteins were renatured and probed with 65ZnCl2. Zinc-binding proteins were
visualized by autoradiography. Positive control: 10 μg bovine carbonic
anhydrase. Negative control: 10 μg of soybean trypsin inhibitor. (B) The
HCCH motif is required for purification by zinc-charged matrix. Purified wild-
type or mutant Vif proteins were treated with factor Xa followed by incubation
with zinc-charged or zinc-free chelating resin. Eluted proteins were analyzed by
SDS-PAGE and immunoblotting.
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effect (Fig. 3E). The RK121/122AA Vif mutant retained a
wild-type phenotype, efficiently co-precipitating Cul5 and
degrading A3G (Figs. 3F and G). These data suggest that the
hydrophobic motif within the zinc-binding domain of HIV-1
Vif forms a critical functional interface with Cul5. Disruption
of this motif results in a defective Vif that is unable to recruit
Cul5 to degrade A3G.
Regions of Cul5 that do not participate in ElonginC binding
are required for interaction with HIV-1 Vif
Primate lentiviral Vif proteins selectively assemble with
Cul5 but not Cul2. Since both Cul2 and Cul5 use ElonginsB/C
as adaptor molecules, the existence of an additional region in
Cul5 that mediates direct interaction between Cul5 and Vif is
likely. While, based on homology to Cul1, the overall folding of
the N-terminal regions of Cul5 and Cul2 is similar, close
examination of the N-terminal regions of Cul5 and Cul2
revealed a major difference (Fig. 4A): the region between helix
5 and helix 7 in Cul2 (Fig. 4A) is considerably longer than thecorresponding region in Cul5 (Fig. 4B). To identify regions of
Cul5 contributing to the selective interaction between Cul5 and
Vif, we constructed a series of in-frame deletion mutants of
Cul5 and studied their interaction with HIV-1 Vif and
ElonginsB/C (Fig. 4C).
Helices 2 and 5 of Cul1 play important roles in mediating
binding to the adaptor molecule Skp1 (Zheng et al., 2002). It has
been predicted that the adaptor molecule ElonginC may bind to
Cul5 in a similar fashion (Zheng et al., 2002). Indeed, efficient
interaction between Cul5 and ElonginC required both helix 2
and helix 5. Mutations that include deletions of helix 2
(Cul5ΔN1) and helix 5 (Cul5ΔN3) significantly decreased
mutant Cul5 binding to ElonginsB/C (Fig. 5A, lanes 2 and 4)
when compared to wild-type Cul5 (Fig. 5A, lane1). In addition,
Cul5ΔN2, which is missing H3 and portions of H4 also lost
interaction with ElonginsB/C (Fig. 5A, lane 3). Deletion of
amino acids 120 to 138 in Cul5 (Cul5ΔN4), which are
downstream from helix 5, did not significantly affect Cul5
binding to ElonginsB/C (Fig. 5A, lane 5) when compared to
wild-type Cul5 (Fig. 5A, lane 1). However, the interaction of
Cul5ΔN4 with HIV-1 VifL145A (Fig. 5B, lane 2) was
significantly reduced when compared to wild-type Cul5 (Fig.
5B, lane 1). This interaction was indeed ElonginB/C-indepen-
dent, since HIV-1 VifL145A cannot interact with ElonginC (Yu
et al., 2004c) yet maintained interaction with wild-type Cul5.
Interaction of VifL145A with wild-type Cul5 was apparently
mediated through the zinc-binding domain, since mutation in
this region (VifL145A/C133S) drastically reduced the interac-
tion with Cul5 (Fig. 5C, lane 2) when compared to VifL145A
(Fig. 5C, lane 1). These results further strengthen the argument
that there is an interface between Vif and Cul5 that is ElonginB/
C-independent. This unique interaction between HIV-1 Vif and
Cul5 requires the HCCH motif in Vif and amino acids 120–138
of Cul5. Cul5 mutants ΔN1–3 also lost interaction with HIV
Vif, but we did not use these mutants for further analysis since
we were looking for an ElonginB/C-independent interface
(Supplementary Fig. 1).
HIV-1 Vif interacts with Cul5 mutants that have lost the ability
to bind ElonginC, and this interaction requires the HCCH
motif
Deletion of helix 2 (Cul5ΔN1) significantly inhibited the
binding of mutant Cul5 to ElonginsB/C when compared to
wild-type Cul5 (Fig. 5A). We hypothesized that if HIV-1 Vif
could interact with Cul5 through a region independent of
ElonginC, then Cul5ΔN1 should still bind HIV-1 Vif, albeit at a
lower efficiency than did wild-type Cul5. Indeed, Cul5ΔN1 co-
precipitated HIV-1 Vif (Fig. 6A, lane 2). Since this interaction
was mainly mediated by the HCCH motif and a region in Cul5
(Fig. 6C), it was weaker than the co-precipitation of Vif and WT
Cul5 (Fig. 6A, lane 1), which relied on the interactions of three
molecules (Fig. 6B). Interaction between Cul5ΔN1 and HIV-1
Vif was disrupted when the HCCH motif was mutated (Fig. 6A,
lane 3). This result was expected, since the only remaining
interface between Vif and Cul5 was abolished (Fig. 6D). These
data, taken together combined with those presented in Fig. 5,
Fig. 3. Hydrophobic amino acids within the zinc-binding region are required for Vif function. (A) The central portion of the HCCH motif is predicted to form a helix
with a hydrophobic face. The indicated mutants were constructed for the following experiments. (B) The hydrophobic residues are required for interaction of Cul5 with
the Vif CRL. 293T cells were transfected with the indicated Vif-HA plasmids. Lysates were immunoprecipitated with HA affinity matrix and analyzed by SDS-PAGE
and immunoblotting to detect interaction with Cul5, ElonginB, and ElonginC. (C) Mutation of the indicated hydrophobic residues results in inhibition of A3G
degradation. 293T cells were co-transfected with wild-type Vif or its mutants and A3G. Cells were harvested and analyzed by SDS-PAGE, followed by
immunoblotting to detect intracellular levels of A3G and Vif. Ribosmal p19 was detected as a loading control. (D) Vif mutants retain interaction with A3G. 293T cells
were co-transfected with wild-type or mutant HA-tagged Vif and A3G plasmids. Cells were harvested and lysates were immunoprecipitated with anti-HA affinity
matrix and analyzed by immunoblotting. (E) Hydrophobic Vif mutants cannot rescue HIV-1 ΔVif virus in the presence of A3G. 293T cells were co-transfected with
HXB2Neo ΔVif virus, A3G, and wild-type or mutant Vif or control vector. After 48 h, virus was collected and used for a MAGI assay. Relative infectivity was
expressed as a percent relative to WT. (F) The basic residues R121 and K122 are not required for interaction with Cul5. 293T cells were transfected with the indicated
Vif-HA plasmids or empty vector control. Lysates were immunoprecipitated with anti-HA affinity matrix and analyzed by SDS-PAGE and immunoblotting to detect
interaction with Cul5, ElonginB, and ElonginC. (G) Mutation of the basic residues, R121 and K122, does not effect Vif degradation of A3G. 293T cells were co-
transfected with wild-type Vif or its mutants and A3G. Cells were harvested and analyzed by SDS-PAGE, followed by immunoblotting. Ribosomal p19 was detected
as a loading control.
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and Cul5.
Discussion
In this study, we have identified a previously unrecognized
mechanism for the assembly of Cullin-RING E3 ubiquitin
ligases (CRL). Our findings indicate that the assembly of Vif-Cul5 E3 ubiquitin ligases requires a hydrophobic interface
within a novel zinc-binding domain in the substrate receptor
Vif and a unique region in Cul5. Given that the role of
substrate receptors in the assembly of CRL is poorly
understood in general, our findings should facilitate further
studies in this area.
Primate lentiviral Vif proteins have been recently identified
as viral substrate receptor molecules that selectively assemble
Fig. 4. Deletion of a flexible loop region of Cul5 results in decreased Vif interaction; however, it has no effect on the ElonginB–ElonginC interaction. (A, B) Models of
Cul2(A) and Cul5(B) generated by 3D-JIGSAW Comparative Modeling Server based on Cul1 template (PDB:1ldjA) (Bates et al., 2001). Relevant regions of the
proteins are illustrated. H2 and H5, helices implicated in Skp1 and ElonginC interaction, are colored orange. Cul5ΔN4 loop is circled, and the analogous loop is circled
in Cul2. (C) Figure illustrating Cul5 deletion mutants constructed for this project.
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specific BC-boxes (Luo et al., 2005). These proteins share a
highly conserved HCCH motif with the consensus H-x5-C-
x17–18-C-x3–5-H. Initial experiments in our laboratory de-
monstrated that the conserved His and Cys residues were
required for Vif recruitment of Cul5 and degradation of A3G.
Further inspection of the HCCH spacing led us to hypothesize
that these residues form a zinc-binding domain. While zinc
fingers were initially associated with nucleic acid-binding
properties such as those displayed by transcription factors,
they are also involved in protein–protein interactions
(Krishna et al., 2003).
Using a 65Zn-blotting assay and zinc affinity chromatog-
raphy, we have determined that HIV-1 Vif is indeed a zinc-
binding protein. Mutation of critical His and Cys residues
resulted in a drastic reduction of zinc binding. We also
detected wild-type Vif from transfected 293T cells bound to
the zinc charged chromatography column and not the control
matrix (data not shown); however, these results are less
reliable than those obtained from purified protein due to the
fact that there may be other Zn binding proteins interacting
with Vif and therefore we still would not know if Vif itself is
a Zn binding protein or if one of its cellular partners is in fact
actually binding Zn. Also, there are many zinc-binding
proteins in the cell that may compete with Vif binding of the
zinc matrix, yielding a result not representative of the zinc-
binding properties of Vif itself. In order to directly address,
the Zn binding ability of Vif, we used purified recombinantprotein, which we demonstrate to efficiently bind zinc
through the HCCH motif.
The conserved HCCH motif of Vif is a unique zinc-
binding motif that is distinct from all other known classes of
zinc-binding domains (Krishna et al., 2003). To our
knowledge, Vif represents the first example of a substrate
receptor molecule that requires zinc for CRL assembly and
function.
Protein structures are frequently stabilized by zinc binding
(Krishna et al., 2003). Our examination of primate lentiviral
Vif proteins identified four hydrophobic amino acids that are
highly conserved (Fig. 1A), and secondary structure consen-
sus programs predicted the presence of the helix with
consensus F-X4-Φ-X2-A-Φ spanning residues 117–125 of
HIV-1 Vif. We hypothesized that a helical structure with a
hydrophobic face within the zinc-binding domain is available
for interaction with Cul5. Consistent with this prediction,
mutation of these hydrophobic residues specifically disrupted
the Vif–Cul5 interaction. The interactions between these
mutant Vif molecules and ElonginC or the target protein A3G
were not affected. However, the mutant Vif molecules were
unable to induce the degradation of A3G, and they lost the
ability to suppress the antiviral function of A3G. Interestingly,
mutation of the basic residues R121 and K122 had no effect
on Vif function. It is possible that these residues are on
another face of the helix that does not come in contact with
Cul5. Another explanation may be that the interaction
between Cul5 and Vif is primarily mediated via hydrophobic
Fig. 5. HIV-1 Vif interacts with a unique, ElonginB–ElonginC-independent, Cul5 interface. (A) ElonginB–ElonginC interacts with Cul5 through an N-terminal
interface that includes amino acids 37–52 and 105–112. 293T cells were transfected with the indicated c-myc-tagged Cul5 plasmids. Cells were harvested, and lysates
were immunoprecipitated with anti-c-myc and protein G. Samples were analyzed by immunoblotting with anti-c-myc, -ElonginB, and -ElonginC. (B) Vif interacts with
Cul5 via an ElonginB–ElonginC-independent mechanism. 293T cells were co-transfected with HA-tagged Vif L145A, which cannot interact with ElonginB–
ElonginC, and c-myc-tagged Cul5. Cells were lysed and incubated with anti-c-myc and protein G. Samples were analyzed by immunoblotting for HA and c-myc. (C)
The Vif zinc finger is required for BC-box-independent Cul5 interaction. 293T cells were co-transfected with HA-tagged Vif L145A or L145A/C133S and c-myc-
tagged Cul5. Cells were lysed and incubated with anti-c-myc and protein G. Samples were analyzed by immunoblotting for HA and c-myc.
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have no effect, as was observed.
The interfaces of Cul5 that mediate substrate receptor
binding are poorly defined. By analogy to the crystal
structures of Cul1 and Skp1, one would predict that the N-
terminal regions of Cul5 (especially helices 2 and 5) are
required for interaction with ElonginC (Zheng et al., 2002).
Consistent with this idea, deletions of helix 2 (Cul5ΔN1) or 5
(Cul5ΔN3) disrupted mutant Cul5 interaction with ElonginC
(Fig. 5A). In addition, deletion of H3 and portions of H4
(Cul5ΔN2) affected ElonginB/C interaction. This is presum-
ably due to the requirement for a certain orientation of H2
and H5. Deletion of the region between these two critical
helices would likely have an effect on the helical organiza-
tion, blocking ElonginB/C interaction. Interestingly, deletion
of a flexible loop structure downstream from helix 5
(Cul5ΔN4) had little effect. This loop region is the most
divergent part between Cul2 and Cul5. Deletion of this loop
region inhibited the binding of mutant Cul5 to HIV-1 Vif
(Figs. 5B and C). This finding raises the intriguing possibility
that this loop region may participate directly in Vif binding.
Alternatively, deletion of this region may alter surrounding
structures in Cul5 that mediate Vif binding. Further biochem-ical and structural studies will be needed to identify the precise
regions of Cul5 that are involved in Vif binding. This
information will be important for our understanding of the
assembly and function of CRL.
The data that we present here is of interest to both
virologists and cell biologists as it demonstrates a novel
method of CRL assembly that can be exploited for antiviral
therapy development. Strategies that selectively target the
zinc-binding domain of Vif or its unique hydrophobic motif
could form the basis for the development of such novel
therapeutics.
Materials and methods
Plasmid construction
Plasmids HXB2neoΔVif, VR1012, pHIV-1Vif-HA, pVi-
fL145A-HA, pMBP-Vif, pCul5-HA, pCul5-myc, pCul5ΔN1,
pCul5ΔN2, and phApo3G-HA have been described (Detten-
hofer and Yu, 1999; Luo et al., 2005; Yu et al., 2003, 2004b).
pMBP-Vif-HCCH/LSSL was made from pMBP-Vif by
changing both H108 and H139 to L and both C114 and
C133 to L. pVifF115A-HA, pVifI120S-HA, and pVifAL123/
Fig. 6. HIV-1 Vif interacts with Cul5 through an HCCH-dependent mechanism.
(A) HIV Vif requires an intact HCCH motif to maintain interaction with Cul5 in
the absence of ElonginB–ElonginC. 293T cells were transfected with the
indicated c-myc-tagged Cul5 and HA-tagged Vif plasmids. Cells were harvested,
and lysates were immunoprecipitated with anti-c-myc and protein G. Samples
were analyzed by immunoblotting for c-myc, HA, ElonginB, and ElonginC. (B–
D) Figure depicting the mechanism of Vif interaction with Cul5 and ElonginC.
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I120 to S, and both A123 and L124 to S, respectively.
pVifL145A/C133S-HA was generated from pVifL145A-HA
by changing C133 to S. pCul5ΔN3 and pCul5ΔN4 were
made from pCul5-myc by deleting amino acids 100–116 or
120–138 of Cul5. HA-tagged human Cul1, Cul2, and Cul3
were a generous gift of Wade Harper and Jianping Jin
(Department of Pathology, Harvard Medical School, Boston,
MA). HA-tagged SOCS3 was a generous gift from Nicholas
A. Cacalano (UCLA).
Cell culture, transfection, MAGI assay, and antibodies
293T and MAGI-CCR5 (AIDS Research Reagents Prog-
ram) cells were maintained and transfected or infected as
previously described (Chackerian et al., 1997; Yu et al.,
2003). The MAGI assay was performed as describedpreviously (Chackerian et al., 1997). The antibodies used in
this study have been described (Yu et al., 2003): anti-HA
antibody-agarose conjugate, anti-myc antibody-agarose con-
jugate, anti-Vif (AIDS Research Reagents Program), anti-
ElonginB, anti-ElonginC, anti-Myc, anti-HA, and anti-human
ribosomal P antigens.
Recombinant MBP fusion protein expression and purification
MBP fusion proteins were expressed in BL21 Star competent
cells (Invitrogen). Bacteria were grown in 20 ml LB at 37 °C
overnight, diluted in 500 ml LB and grown to an OD600 of 0.5.
0.3 mM IPTG was added to culture and incubated at 20 °C for
10 h. Cells were harvested by centrifugation, and pellet was
resuspended in 10 ml lysis buffer (20 mM sodium phosphate
buffer pH 6.5, DNAse 25 ng/ml, 1 mM PMSF, 10 μg/ml
lysozyme). Lysate was sonicated on ice and centrifuged at
10,000 rpm for 30 min. Supernatant was collected for protein
purification.
A 10 ml column was packed with amylose resin and
washed with 8 volumes of column buffer. Samples were
loaded onto the column and incubated, shaking, for 30 min
at 4 °C. Resin was washed 3 times with wash buffer
(20 mM Tris–HCl, pH 7.5, 0.1 M NaCl, 0.1 mM EDTA,
0.1% Tween-20). Protein was eluted with 1.5 volumes of
100 μM maltose in column buffer. Eluted proteins were
treated with Factor Xa (New England, BioLabs) for 4 h at 25
°C to remove the MBP tag.
Zinc blotting
Zinc blotting experiments were carried out as described
(Boyer and Ketner, 2000). In brief, recombinant fusion
proteins MBP-Vif and pMBP HCCH/LSSL were induced
and expressed in bacteria, and the crude extracts were applied
to an amylose column for purification of MBP fusion
proteins. 15 μg of the eluted proteins was treated with Factor
Xa (New England, BioLabs) for 4 h at 25 °C to remove MBP.
Proteins were run on SDS-PAGE with 10 μg each of carbonic
anhydrase and soybean trypsin inhibitor as positive and
negative controls, respectively, and transferred to a nitrocel-
lulose membrane using a semi-dry apparatus (Bio-Rad). The
membrane was incubated in 25 ml of denaturation buffer
(20 mM HEPES, pH 7.9, with 60 mM KCl, 6 mM MgCl2,
and 0.6 mM EDTA) supplemented with 6 M guanidine-HCl,
2 mM dithiothreitol, and 10% glycerol for 30 min at room
temperature. The membrane was then incubated with two
changes (2 h each at room temperature) of 25 ml renaturation
buffer supplemented with 100 mM guanidine HCl, 0.02%
polyvinylpyrrolidone, 2 mM dithiothreitol, and 10% glycerol
and with a single change (30 min at room temperature) of
25 ml renaturation buffer. The blots were equilibrated in
metal binding buffer (0.1 M Tris, pH 6.8, 50 mM NaCl) for
1.5 h at room temperature and probed with 65Zn at 4 μCi/ml
in metal binding buffer for 80 min at room temperature. After
the blots were washed three times (10 min each) with 10 ml
of metal binding buffer, the zinc bound by the immobilized
298 Z. Xiao et al. / Virology 349 (2006) 290–299protein was visualized by autoradiography. Experiments were
repeated three times, and the band intensities were quantified.
Zinc affinity chromatography
Zinc affinity chromatography experiments were carried out
as described (Bragg et al., 2004). A zinc affinity column was
constructed for chromatography by using 0.5 ml of chelating
Sepharose fast-flow resin (Amersham) that had been charged
with zinc for immobilized metal affinity chromatography as
described by the manufacturer. The resin was poured into 2-ml
chromatography columns, washed twice with 2 ml deionized
water, and then incubated with 150 mM ZnSO4 at room
temperature for 30 min. The resin was washed twice with
deionized water, followed by two washes with 2 ml acidic
buffer (20 mM sodium acetate, pH 3.0, with 750 mM NaCl).
The resin was then equilibrated at 4 °C with 2 ml binding buffer
(20 mM NaPO4, pH 7.0, 500 mM NaCl). After the resin settled,
the protein extract, MBP-Vif, or pMBP-Vif HCCH/LSSL
(1.5 ml) was applied to the column at the rate of 4 drops/min
(∼200 μl/min). The column was washed three times with 2 ml
of the zinc column binding buffer. Proteins were eluted using
200 μl acidic buffer. For the control experiments, the protein
extracts were applied to a column that contained chelating
Sepharose fast-flow resin that had not been charged with zinc.
All experiments were repeated three times, and band intensities
were quantified.
Immunoprecipitation and immunoblot analysis
Transfected 293T cells were harvested, washed twice with
cold PBS, and lysed in lysis buffer (50 mM Tris, pH 7.5, with
150 mM NaCl, 1% Triton X-100, and complete protease
inhibitor cocktail tablets) at 4 °C for 1 h, then centrifuged at
10,000×g for 30 min. For myc-tag immunoprecipitation,
precleared cell lysates were mixed with anti-myc antibody
(Upstate) and incubated with protein G at 4 °C for 3 h. For HA
tag immunoprecipitation, precleared cell lysates were mixed
with anti-HA antibody-conjugated agarose beads (Roche) and
incubated at 4 °C for 3 h. Samples were then washed three times
with washing buffer (20 mM Tris, pH 7.5, with 100 mM NaCl,
0.1 mM EDTA, and 0.05% Tween-20). The beads were eluted
with elution buffer (0.1 M glycine–HCl, pH 2.0) or 2× loading
buffer. The eluted materials were then analyzed by SDS-PAGE
and immunoblotting with anti-Vif (AIDS Research Reagents
Program) as previously described (Yu et al., 2003).
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